Weight Loss Guide

Tirzepatide for Weight Loss

FDA-approved dual-agonist (sold as Mounjaro and Zepbound). The best balance of weight loss efficacy, safety data, and tolerability currently available.

22.5%

Avg Weight Loss

72 weeks

Trial Duration

Weekly

Frequency

FDA Approved

Status

Why Tirzepatide is the Most Popular Choice

Extensive Safety Data

FDA-approved with large Phase 3 SURMOUNT trials involving thousands of participants. Most well-studied weight loss peptide available.

Excellent Tolerability

The GIP component reduces nausea significantly compared to GLP-1-only drugs. Most users find it better tolerated than equivalent-dose Semaglutide.

Proven Results

22.5% average weight loss in SURMOUNT-1 trial. 87% of participants achieved at least 5% weight loss. Real-world results consistently match trials.

Standard Titration Protocol

Phase	Dose	Duration	Expected Effect
Starting	2.5mg	Weeks 1–4	Tolerance building, mild appetite changes
Titration 1	5mg	Weeks 5–8	Clear appetite suppression, first weight loss
Titration 2	7.5mg	Weeks 9–12	Accelerated fat loss
Titration 3	10mg	Weeks 13–16	Near maximum therapeutic effect
Target	10–15mg	Ongoing	Maintenance and continued loss

Note: Generic research Tirzepatide may be dosed differently than pharmaceutical Mounjaro pens. Verify mg per unit with your supplier.

Expected Results Timeline

2.5mg Phase

Subtle appetite changes. Some users notice less interest in food. Minimal weight loss at this dose — it's primarily a tolerance-building phase.

5–7.5mg Phase

Clear, noticeable appetite suppression. Food intake drops naturally. Weight loss becomes consistent — typically 0.5–1.5kg per week.

10–15mg Phase

Maximum weight loss phase. Many users describe near-complete suppression of hunger. Rapid body composition changes. 10–20% total loss achievable.

Long-term

Weight loss slows as body weight decreases (fewer calories to cut). Maintenance becomes the goal. Many users stay at 10mg long-term.

Not Losing Weight?

If you're not losing weight on 2.5mg, this is expected — it's a titration dose. Increase to 5mg after 4 weeks.

At 5mg+, if weight stalls: track actual caloric intake. Tirzepatide suppresses hunger but doesn't prevent eating above maintenance.

Check that you're using subcutaneous injection correctly (not intramuscular, not intravenous).

Ensure peptide is being stored correctly (refrigerated, not frozen after reconstitution).

Verify COA and product authenticity — underdosed or counterfeit product is a common cause.

Medical causes: thyroid issues, medications that cause weight gain, or metabolic adaptation — consult a doctor.

Rebound Warning: Weight typically returns if Tirzepatide is discontinued without lifestyle changes. The peptide suppresses appetite — when stopped, appetite returns to baseline. Maintain dietary habits and exercise routine learned during treatment.

Full Tirzepatide Guide Compare: Retatrutide Compare: Semaglutide Not Losing Weight FAQ View Supply Index